Sean McBride, Chief of External Beam Radiotherapy and Associate Attending of Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, shared a post on X:
“Wanted to highlight our AASUR trial. Was an awesome multi-institutional collaboration. Especially grateful to The PCCTC and UMich Rad Onc team (Daniel E Spratt, Jason Hearn, et al were our 2nd leading accruers). But a true team effort.
And many thanks to JandJ Innovative Medicine and Prostate Cancer Foundation for funding.
TL;DR: in VHR localized PCa, a short course (6mo), ADT/ARPI regimen combined with 40/5 prostate-only SBRT had favorable toxicity profile, rapid T return, and, despite not meeting superiority threshold, BCR rates that looked similar to long course ADT historical controls. These patients were not DECIPHER-selected or PSMA PET staged.
It may be that scADT/ARPI+RT would provide equivalent results in the vast majority of RT-treated VHR, localized dz. Obviously this would require confirmation in an appropriately sized NI trial.”
Title: Apalutamide + Abiraterone acetate plus Prednisone (AAP) + Leuprolide with Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase 2 Study
Authors: Sean M. McBride, Daniel E. Spratt, Marisa Kollmeier, Wassim Abida, Han Xiao, Susan F. Slovin, Channing J. Paller, Curtiland Deville, Robert B. Den, Jason Hearn, Victoria Catharine, Howard Scher, Michael Zelefsky, Dana Rathkopf
Read the Full Article.
Other articles about prostate cancer on OncoDaily.